Arcellx, Inc. is a biotechnology company focused on developing innovative immunotherapies for patients with cancer and other incurable diseases. The company's lead products include anitocabtagene autoleucel and ACLX-001, both of which are in clinical trials for the treatment of multiple myeloma and other related conditions.

Arcellx

Arcellx, Inc.

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Arcellx, Inc. Common Stock

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

COM:ARCELLX

Arcellx, Inc.

Last Close

63.31

13/02 14:59

Market Cap

3.42B

Beta: -

Volume Today

468.71K

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

revenue

Description

peer of

competitor of

Metrics